- CITATIONS: 1
|Application ||WB, IHC-P, E|
|Other Accession||P18287, P10517|
|Calculated MW||36154 Da|
|Antigen Region||263-292 aa|
|Other Names||Apolipoprotein E, Apo-E, APOE|
|Target/Specificity||This APOE antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 263-292 amino acids from the C-terminal region of human APOE.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||APOE Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.|
|Tissue Location||Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle|
Provided below are standard protocols that you may find useful for product applications.
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III),in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.
Wood,K.C., Appl Physiol Nutr Metab 33 (4), 761-768 (2008) Pemberton,L., (er) HIV Med. (2008) In press Sundermann,E.E., (er) Horm Behav (2008) In press Christensen,H.,(er) BMC Geriatr 8, 14 (2008)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.
1 2 3 4 5
1. Block with 3% skim milk for 1 hour at room temperature. 2. Incubate overnight with Abgent primary antibody 1:1000 in 3% skim milk at 4℃ 3. Wash 5*5 min with TBST. 4. Incubate with HRP-conjugated secondary antibody 1:5000 in 3% skim milk for 1 hour at room temperature. 5. Wash 5*5 min with TBST. 6. Incubate with ECL substrates and expose